BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10621	Companies
225706	Keywords
154266	Articles
119431	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 04/14/2026 at 09:05, 2 months 9 days ago

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
BioNxt announces successful completion of GMP manufacturing for sublingual Cladribine oral thin film, advancing to clinical-stage execution. Company aims to treat MS and neurodegenerative diseases

GMP Manufacturing Sublingual Cladribine MS Treatment BioNxt Clinical-stage Execution
BRIEF

published on 04/07/2026 at 09:10, 2 months 16 days ago

BioNxt Solutions obtient un brevet européen pour sa plateforme de cladribine sublinguale

Solutions BioNxt Brevet Européen Administration De Médicaments Cladribine Sublinguale Plateforme ODF
BRIEF

published on 04/07/2026 at 09:10, 2 months 16 days ago

BioNxt Solutions Secures European Patent for Sublingual Cladribine Platform

Drug Delivery European Patent BioNxt Solutions Sublingual Cladribine ODF Platform
PRESS RELEASE

published on 04/07/2026 at 09:05, 2 months 16 days ago

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
BioNxt Solutions Inc. secures Unitary Patent registration for sublingual cladribine oral thin film technology in Europe, enhancing commercialization prospects and partnership opportunities

BioNxt Solutions Inc. Drug Delivery European Patent Sublingual Cladribine Unitary Patent
BRIEF

published on 03/30/2026 at 09:10, 2 months 24 days ago

BioNxt Progresses with Semaglutide ODF Program

Semaglutide Peptide Therapeutics BioNxt GLP-1 Platform ODF Strategy
BRIEF

published on 03/30/2026 at 09:10, 2 months 24 days ago

BioNxt progresse dans son programme ODF sur le sémaglutide

Semaglutide BioNxt Plateforme GLP-1 Stratégie ODF Thérapeutiques Peptidiques
PRESS RELEASE

published on 03/30/2026 at 09:05, 2 months 24 days ago

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Solutions Inc. provides update on semaglutide ODF program and platform strategy. Focus on GLP-1 receptor agonists and peptide-based therapeutics. Potential market growth and commercial outlook discussed

GLP-1 Receptor Agonists BioNxt Solutions Market Opportunity Peptide-based Therapeutics Semaglutide ODF Program
BRIEF

published on 03/24/2026 at 10:15, 2 months 30 days ago

BioNxt Advances Commercial Strategy with Global Patents and U.S. Fast Track

Commercialization Pharmaceutical Partnerships BioNxt Solutions Sublingual Drug Delivery Global Patent
BRIEF

published on 03/24/2026 at 10:15, 2 months 30 days ago

BioNxt fait progresser sa stratégie commerciale grâce à des brevets mondiaux et à une procédure d'autorisation accélérée aux États-Unis.

Commercialisation Partenariats Pharmaceutiques Solutions BioNxt Administration Sublinguale De Médicaments Brevet Mondial
PRESS RELEASE

published on 03/24/2026 at 10:10, 2 months 30 days ago

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
BioNxt Solutions Inc. announces major advancement in commercialization strategy with global patent portfolio expansion for sublingual drug delivery platform. Strong intellectual property and transitioning to commercialization phase

BioNxt Solutions Inc. Intellectual Property Commercialization Drug Delivery Systems Global Patents

Accesswire

Published on 06/24/2026 at 03:15, 1 hour 12 minutes ago

Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 4 hours 27 minutes ago

Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 4 hours 42 minutes ago

Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 5 hours 7 minutes ago

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 5 hours 12 minutes ago

EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects

View all ACCESSWIRE

EQS Group

Published on 06/24/2026 at 04:00, 26 minutes ago

Shipping edges closer to onboard carbon mineralisation as IMO endorses Shanghai Qiyao Technology Group Co., Ltd. proposals
Published on 06/24/2026 at 02:05, 2 hours 21 minutes ago

FRONTERA AND KUPARI ANNOUNCE COMMENCEMENT OF STRATEGIC SALE PROCESS FOR THE JOINTLY OWNED PIEDRAS VERDES COPPER MINE COMPLEX IN SONORA, MEXICO
Published on 06/23/2026 at 22:20, 6 hours 6 minutes ago

Saudi Properties Portal to Accept Applications for Foreign Real Estate Ownership
Published on 06/23/2026 at 20:15, 8 hours 12 minutes ago

EQS-Adhoc: OHB SE resolves on the issue of 1,605,388 new shares representing the first tranche of the up to 8.86% capital increase with subscription rights
Published on 06/23/2026 at 18:59, 9 hours 28 minutes ago

Holding(s) in Company

Les Echos

Published on 06/23/2026 at 19:47, 8 hours 39 minutes ago

GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 8 hours 39 minutes ago

GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 9 hours 16 minutes ago

GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 9 hours 16 minutes ago

GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
Published on 06/23/2026 at 18:32, 9 hours 54 minutes ago

Communiqué sur la demande de radiation auprès d'Euroclear des Droits à Complément de Prix

View all LES ECHOS COMFI WIRE